New queries are now available for beta testing under “FDA Marker Queries”. They allow you to search for in vitro and clinical data for inhibitors of CYP markers, and, in a second step from the query results page, view clinical concentrations of each inhibitor.
We are looking forward to your feedback!
The DIDB Team will release new features on Saturday April 6, 2019. The release includes the following improvements:
- Revised home page with a new “Latest NDAs entered” section.
- Added number of entries (studies) to standard citation info.
- Added new monograph page for all compounds.
- This new monograph page combines the previously separate PK summary, QT summary, and monograph into a single page.
- What was formerly known as “Monograph” is now “DDI summary” and has been renamed throughout application.
- New monograph page also aggregates some other additional information on each compound such as DIDB defined compound relationships, other properties from DIDB, and some selected external resources.
- Every compound has a monograph page, but many compounds may not have a DDI, PK, or QT summary, so there may be very little information presented.
- In Resource Center, added listings of all compounds in each therapeutic class, including DDI risk information. This new therapeutic class information is a replacement for the DDI risk information which was presented in the Disease section. The entire Disease section has been removed.
- In Resource Center, added two new listings – all compounds with DDI Summaries and all compounds with PK Profiles.
- Removed pdf product labels and replaced with link to Drugs@FDA when an NDA is related to the drug.
Do not hesitate to contact us at firstname.lastname@example.org if you have any feedback or questions!
The following new features have been implemented:
- New DRUG query where you can find all studies in DIDB for a given compound, including in vitro transporter data
- Unified in vivo measurement types across all study types
- Unified citation tree view of all in vivo studies
- Measurement types now displayed in their proper subscript formats
- Tree view now more easily viewable on phones
- New “In Vivo Other Mechanism” sub-type of “PD interaction”
Do not hesitate to contact us at email@example.com if you have any questions or suggestions!
The DIDB program is pleased to announce the release of e-PKGene Version 2.0.
Please see this detailed description of the new features.
New features include:
- A new responsive design that works on phones and tablets.
A set of new quantitative searches:
Users are now able to select a combination of factors (compounds, genes, ethnicities) to query for quantitative measurements. Tabular results are provided in % ∆ from the reference population’s measurements and provide both pharmacokinetic (PK) and pharmacodynamic (PD) data.
These results can be further refined by filtering individual columns by text or by a numerical range. Columns can also be reordered or hidden from view. With these tools, users can explore the initial result set and refine the data to their needs. The data then can be saved as a spreadsheet.
New design for displaying full citation and NDA information:
For each study, all information has been condensed into a single, easy to understand table. Measurement data for the citation/NDA can be viewed in the same manner as the quantitative results query by clicking on the “% ∆ data” link in the description section.
At the top of the citation navigation menu, “PK”, “PD”, and “Side Effects” buttons are highlighted only if the citation contains data for it; one click on either button will hide the information which is not of interest.
needs. The data then can be saved as a spreadsheet.
- Updated drug summaries